Compass Therapeutics Announces Key Leadership Appointments

Core Insights - Compass Therapeutics, Inc. has appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, effective January 1, 2026, to enhance its leadership team in oncology-focused biopharmaceutical development [1][2] Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for multiple human diseases, particularly in oncology [4] - The company aims to target critical biological pathways necessary for effective anti-tumor responses, including angiogenesis modulation and immune response activation [4] Leadership Experience - Arjun Prasad brings extensive experience in oncology product launches, having successfully led over 10 launches, including the notable VORANIGO® in 2024 and TIBSOVO® for biliary tract cancer [2][3] - Cynthia Sirard has over two decades of experience in oncology drug development, with a focus on gastrointestinal cancers and has led multiple programs through regulatory approval processes [3] Strategic Goals - The appointments of Prasad and Sirard are expected to significantly enhance Compass's ability to deliver innovative therapies, particularly for biliary tract cancer and other oncology indications [2][3] - The company is approaching transformational milestones for its lead candidate, tovecimig, and aims to advance its robust pipeline of therapies [4]